Study rationale and design of the CIMT trial: The Copenhagen insulin and metformin therapy trial

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 315-322

  Lundby Christensen, Louise ^a   Almdal, T ^b   Boesgaard, T ^a   Breum, L ^c   Dunn, E ^d   Gade Rasmussen, B ^e   Gluud, C ^f   Hedetoft, C ^c   Jarloev, A ^e   Jensen, T ^f   Krarup, T ^g   Johansen, L B ^h   Lund, S S ^a   Madsbad, S ^b   Mathiesen, E ^f   Moelvig, J ^h   Nielsen, F ^d   Perrild, H ^g   Pedersen, O ^a   Roeder, M ⁱ   Sneppen, S B ^d   Snorgaard, O ^b   Tarnow, L ^a   Thorsteinsson, B ⁱ   Vaag, A ^a   Vestergaard, H ^d   Wetterslev, J ^f   Wiinberg, N ^e   more..

^a STENO DIABETES CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Department of Medicine   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e FREDERIKSBERG HOSPITAL   (Denmark)

^f Rigshospitalet   (Denmark)

^g BISPEBJERG HOSPITAL   (Denmark)

^h AMAGER HOSPITAL   (Denmark)

ⁱ HILLERØD HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Insulin; Intima media thickness; Metformin; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN; LONG ACTING INSULIN;

ACUTE HEART INFARCTION; ADULT; AGED; AMPUTATION; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BEDTIME DOSAGE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FATALITY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; EPIDEMIOLOGY; INTIMA; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUNICA MEDIA; YOUNG ADULT;

ADULT; AGED; BIPHASIC INSULINS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA; YOUNG ADULT;

EID: 61549090903     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00959.x     Document Type: Article

References (30)

1. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
2. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
3. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
4. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
5. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442-451.
6. Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005; 54: 1-7.
7. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-1426.
8. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet 2006; 368: 29-36.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
12. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, Issue 3. Art. No.: CD002966. DOI: 10.1002/ 14651858.CD002966.pub3
13. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
15. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008; 358: 2633-2635.
16. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007; 46: 734-742.
17. Mudrikova T, Szaboova E, Tkac I. Carotid intima-media thickness in relation to macrovascular disease in patients with type 2 diabetes mellitus. Wien Klin Wochenschr 2000; 112: 887-891.
18. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006; 37: 2420-2427.
19. Lee EJ, Kim HJ, Bae JM et al. Relevance of common carotid intima-media thickness and carotid plaque as risk factors for ischemic stroke in patients with type 2 diabetes mellitus. Am J Neuroradiol 2007; 28: 916-919.
20. Bernard S, Serusclat A, Targe F et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care 2005; 28: 1158-1162.
21. Yamasaki Y, Kodama M, Nishizawa H et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: Predictors of progression and relationship with incident coronary heart disease. Diabetes Care 2000; 23: 1310-1315.
22. Katakami N, Yamasaki Y, Hayaishi-Okano R et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47: 1906-1913.
23. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
24. Langenfeld MR, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
25. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006; 296: 2572-2581.
26. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
27. Touboul PJ, Hennerici MG, Meairs S et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23: 75-80.
28. Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6: 3.
29. International Conference on Harmonisation E9 Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med 1999; 18: 1905-1942.
30. Van Breukelen GJ ANCOVA versus change from baseline: More power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol 2006; 59: 920-925.